{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:53:47Z","timestamp":1789102427024,"version":"build-2803163510"},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whether the immune suppressive action of glucocorticoid steroids, such as dexamethasone, might reduce the benefits of cancer immunotherapy has long been a concern. Observations that established tumor regressions in response to immune checkpoint inhibitors (ICIs) often persist, despite the use of steroids to mitigate ICI-related autoimmune breakthrough, are not sufficiently reassuring, because these observations do not address the potential blunting of immune priming at the initiation of ICI therapy. With increasing indications for ICI in combination with chemotherapy, this issue merits reconsideration. Professional society guidance advises that dexamethasone should be used as first-line prophylaxis for nausea and vomiting in patients receiving ICI and highly emetogenic chemotherapy combination regimens. Here, we review the availability of data on this subject and propose an alternative approach focused on the adoption of steroid minimization or sparing for prophylaxis of nausea until the underlying immune biology is better understood.<\/jats:p>","DOI":"10.1002\/onco.13680","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T19:08:27Z","timestamp":1611083307000},"page":"269-273","source":"Crossref","is-referenced-by-count":41,"title":["Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy"],"prefix":"10.1093","volume":"26","author":[{"given":"Tobias","family":"Janowitz","sequence":"first","affiliation":[{"name":"Cold Spring Harbor Laboratory, New York, Cold Spring Harbor, USA"},{"name":"Cancer Institute, Northwell Health, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Kleeman","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, New York, Cold Spring Harbor, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Vonderheide","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2021122512040407500_onco13680-bib-0001","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists","volume":"76","author":"De Boer-Dennert","year":"1997","journal-title":"Br J Cancer"},{"key":"2021122512040407500_onco13680-bib-0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer"},{"issue":"suppl 5","key":"2021122512040407500_onco13680-bib-0003","first-page":"v119","article-title":"MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol 2016"},{"key":"2021122512040407500_onco13680-bib-0004","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122512040407500_onco13680-bib-0005","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - State of the art","volume":"19","author":"Grunberg","year":"2011","journal-title":"Support Care Cancer"},{"key":"2021122512040407500_onco13680-bib-0006","first-page":"2020","author":"KEYTRUDA (pembrolizumab) injection, for intravenous use. Initial U.S. approval","year":"2014","journal-title":"U.S. Food and Drug Administration"},{"key":"2021122512040407500_onco13680-bib-0007","first-page":"2020","author":"TECENTRIQ (atezolizumab) injection, for intravenous use. Initial U.S. approval","year":"2016","journal-title":"U.S. Food and Drug Administration"},{"key":"2021122512040407500_onco13680-bib-0008","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0009","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0010","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"2021122512040407500_onco13680-bib-0011","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"An open-label, multicenter, phase 1b study evaluating the safety and efficacy of CD40 Agonistic monoclonal antibody APX005M and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma","volume":"22","author":"O'Hara","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122512040407500_onco13680-bib-0012","article-title":"Avoidable acute care use associated with nausea and vomiting among patients receiving highly emetogenic chemotherapy or oxaliplatin","author":"Navari","year":"2020","journal-title":"The Oncologist"},{"key":"2021122512040407500_onco13680-bib-0013","volume-title":"CMS proposes hospital outpatient prospective payment changes for 2017","author":"Centers for Medicare & Medicaid Services","year":"2020"},{"key":"2021122512040407500_onco13680-bib-0014","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0021-9258(18)74051-9","article-title":"Chemical studies of supra-renal cortex iv structure of compounds C-D-E-F and G","volume":"124","author":"Mason","year":"1938","journal-title":"J Biol Chem"},{"key":"2021122512040407500_onco13680-bib-0015","first-page":"181","article-title":"The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis","volume":"24","author":"Hench","year":"1949","journal-title":"Proc Staff Meet Mayo Clin"},{"key":"2021122512040407500_onco13680-bib-0016","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM199610173351607","article-title":"Adrenal insufficiency","volume":"335","author":"Oelkers","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0017","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/jcem-33-1-14","article-title":"Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects","volume":"33","author":"Weitzman","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122512040407500_onco13680-bib-0018","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: Mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2021122512040407500_onco13680-bib-0019","volume-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","author":"Goodman","year":"1996"},{"key":"2021122512040407500_onco13680-bib-0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2021122512040407500_onco13680-bib-0021","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0091270003258651","article-title":"Dose equivalency evaluation of major corticosteroids: Pharmacokinetics and cell trafficking and cortisol dynamics","volume":"43","author":"Mager","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"2021122512040407500_onco13680-bib-0022","first-page":"503","article-title":"Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone","volume":"262","author":"Koopmans","year":"1992","journal-title":"assessed with a pharmacokinetic model. J Pharmacol Exp Ther"},{"key":"2021122512040407500_onco13680-bib-0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1096\/fj.01-0245com","article-title":"Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells","volume":"16","author":"Galon","year":"2002","journal-title":"FASEB J"},{"key":"2021122512040407500_onco13680-bib-0024","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic\u2013pituitary\u2013adrenal axis and immune-mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0025","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment","volume":"53","author":"Acharya","year":"2020","journal-title":"immunity"},{"key":"2021122512040407500_onco13680-bib-0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00258206","article-title":"High-dose dexamethasone for prevention of cis-platin-induced vomiting","volume":"7","author":"Aapro","year":"1981","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122512040407500_onco13680-bib-0027","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","article-title":"Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: Results of a randomized, placebo-controlled phase III Trial","volume":"32","author":"Schmitt","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199501053320101","article-title":"Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer","volume":"332","author":"The Italian Group for Antiemetic Research","year":"1995","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0029","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0030","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00000421-198706000-00021","article-title":"Methylprednisolone for the control of CMF-induced emesis","volume":"10","author":"Chiara","year":"1987","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"2021122512040407500_onco13680-bib-0031","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJM198102193040815","article-title":"Methylprednisolone as an Antiemetic","volume":"304","author":"Lee","year":"1981","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0032","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting","volume":"722","author":"Chu","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2021122512040407500_onco13680-bib-0033","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00000542-200409000-00014","article-title":"Inhibitory effect of glucocorticoids on human-cloned 5- hydroxytryptamine3A receptor expressed in xenopus oocytes","volume":"101","author":"Suzuki","year":"2004","journal-title":"Anesthesiology"},{"key":"2021122512040407500_onco13680-bib-0034","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/1469-8986.3940491","article-title":"Reduction in serum cortisol after platinum based chemotherapy for cancer: A role for the HPA axis in treatment-related nausea?","volume":"39","author":"Morrow","year":"2002","journal-title":"Psychophysiology"},{"key":"2021122512040407500_onco13680-bib-0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.2.6132.253","article-title":"Circadian variation in an immune response in man","volume":"2","author":"Cove-Smith","year":"1978","journal-title":"Br Med J"},{"key":"2021122512040407500_onco13680-bib-0036","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bmj.284.6315.551","article-title":"Circadian variation in disease activity in rheumatoid arthritis","volume":"284","author":"Harkness","year":"1982","journal-title":"Br Med J (Clin Res Ed)"},{"key":"2021122512040407500_onco13680-bib-0037","first-page":"385","article-title":"Waddell WR. THE reversal of rejection in human renal homografts with subsequent development of homograft tolerance","volume":"117","author":"Starzl","year":"1963","journal-title":"Surg Gynecol Obstet"},{"key":"2021122512040407500_onco13680-bib-0038","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122512040407500_onco13680-bib-0039","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti\u2013PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2021122512040407500_onco13680-bib-0041","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab"},{"key":"2021122512040407500_onco13680-bib-0042","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0043","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Ellen Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0044","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"2021122512040407500_onco13680-bib-0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e15133","article-title":"Cumulative steroid doses and response rates to immune checkpoint inhibitors in metastatic cancer","volume":"38","author":"Tawagi","year":"2020","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0046","first-page":"37","article-title":"Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients","volume":"64a","author":"Elias","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0047","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0048","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0049","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"2021122512040407500_onco13680-bib-0050","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2021122512040407500_onco13680-bib-0051","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/ng.2232","article-title":"Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis","volume":"44","author":"Stahl","year":"2012","journal-title":"Nat Genet"},{"key":"2021122512040407500_onco13680-bib-0052","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1922867117","article-title":"Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer","volume":"117","author":"Khan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122512040407500_onco13680-bib-0053","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.critrevonc.2017.10.009","article-title":"Concomitant use of corticosteroids and immune checkpoint inhibitors in patients with hematologic or solid neoplasms: A systematic review","volume":"120","author":"Garant","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021122512040407500_onco13680-bib-0054","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0055","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/annonc\/mdx181","article-title":"Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes","author":"Connell","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122512040407500_onco13680-bib-0056","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0057","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"2021122512040407500_onco13680-bib-0058","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0059","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"2021122512040407500_onco13680-bib-0060","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous nsclc","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512040407500_onco13680-bib-0061","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"2021122512040407500_onco13680-bib-0062","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"27","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"2021122512040407500_onco13680-bib-0063","doi-asserted-by":"crossref","first-page":"883","DOI":"10.6004\/jnccn.2017.0117","article-title":"NCCN Guidelines Insights: Antiemesis, Version 2.2017","volume":"15","author":"Berger","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"2021122512040407500_onco13680-bib-0064","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: A prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"2021122512040407500_onco13680-bib-0065","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.annemergmed.2016.03.017","article-title":"A Randomized controlled noninferiority trial of single dose of oral dexamethasone versus 5\u2009days of oral prednisone in acute adult asthma","volume":"68","author":"Rehrer","year":"2016","journal-title":"Ann Emerg Med"},{"key":"2021122512040407500_onco13680-bib-0066","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.pec.0000248683.09895.08","article-title":"Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma","volume":"22","author":"Altamimi","year":"2006","journal-title":"Pediatr Emerg Care"},{"key":"2021122512040407500_onco13680-bib-0067","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","article-title":"Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy","volume":"36","author":"Ito","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122512040407500_onco13680-bib-0068","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","article-title":"Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Hashimoto","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122512040407500_onco13680-bib-0069","article-title":"Emergency department visits for emesis following chemotherapy: Guideline nonadherence, OP-35, and a path back to the future","author":"Neugut","year":"2020","journal-title":"The Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13680","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13680","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/269\/41923540\/oncolo_26_4_269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/269\/41923540\/oncolo_26_4_269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T17:39:57Z","timestamp":1724348397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/4\/269\/6445565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13680","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,2,26]]}}}